April 25, 2017 (Shareholders Foundation) - An investigation on behalf of investors of ICU Medical, Incorporated (NASDAQ:ICU) shares over potential securities laws violations by ICU Medical, Incorporated and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of ICU Medical, Incorporated (NASDAQ:ICU) concerning whether a series of statements by ICU Medical, Incorporated regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

ICU Medical, Incorporated reported that its annual Total Revenue rose from $341.67 million in 2015 to $379.37 million in 2016 and that its Net Income grew from $44.98 million in 2015 to $63.08 million in 2016.

Shares of ICU Medical, Incorporated (NASDAQ:ICU) grew from $86.47 per share in February 2016 to as high as $158.30 per share in March 2017.

On April 18, 2017, after-market hours, ICU Medical revealed that it had received a subpoena from the U.S. Department of Justice (DOJ) requesting 'documents regarding the manufacturing, selling, pricing and shortages of intravenous solutions, including saline' that it gained when it acquired the infusion systems business of Pfizer Inc.'s Hospira unit.

Shares of ICU Medical, Incorporated (NASDAQ:ICU0 declioned on April 19, 2017 to $144.25 per share.

On April 25, 2017, NASDAQ:ICU shares closed at $150.75 per share.